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Background: Mortality rates for cancer are decreasing in patients under 60 and increasing in those over 60 years of
age. The reasons for these differences in mortality rates remain poorly understood. One explanation may be that
older patients received substandard treatment because of concerns about adverse effects. Given the paucity of
research on the multiple dimensions of the symptom experience in older oncology patients, the purpose of this
study was to evaluate for differences in ratings of symptom occurrence, severity, frequency, and distress between
younger (< 60 years) and older ( ≥ 60 years) adults undergoing cancer treatment. We hypothesized that older
patients would have significantly lower ratings on four symptom dimensions.
Methods: Data from two studies in the United States and one study in Australia were combined to conduct this
analysis. All three studies used the MSAS to evaluate the occurrence, severity, frequency, and distress of 32
symptoms.
Results: Data from 593 oncology outpatients receiving active treatment for their cancer (i.e., 44.4% were < 60 years
and 55.6% were ≥ 60 years of age) were evaluated. Of the 32 MSAS symptoms, after controlling for significant
covariates, older patients reported significantly lower occurrence rates for 15 (46.9%) symptoms, lower severity
ratings for 6 (18.9%) symptoms, lower frequency ratings for 4 (12.5%) symptoms, and lower distress ratings for 14
(43.8%) symptoms.
Conclusions: This study is the first to evaluate for differences in multiple dimensions of symptom experience in
older oncology patients. For almost 50% of the MSAS symptoms, older patients reported significantly lower
occurrence rates. While fewer age-related differences were found in ratings of symptom severity, frequency, and
distress, a similar pattern was found across all three dimensions. Future research needs to focus on a detailed
evaluation of patient and clinical characteristics (i.e., type and dose of treatment) that explain the differences in
symptom experience identified in this study.
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Cancer is predominantly an older person’s illness. Ap-
proximately 50% of the most common cancers (i.e., breast,
prostate, and lung) occur in people over 60 years of age
[1]. Because of major advances in cancer treatment and
supportive care strategies, a larger percentage of older per-
sons are receiving active treatment [2]. However, while
mortality rates for cancer are decreasing in patients under
60, they are increasing in those over 60 years of age [1].
The reasons for these differences in mortality rates remain
poorly understood primarily due to the paucity of research
on older persons with cancer.
Older adults are a vulnerable population who are
at high risk for suboptimal cancer care because they
were under-represented in clinical trials and experience
disparities in cancer treatment [3-7]. One reason why
mortality rates may be increasing in patients over 60 is
that they receive substandard treatment (i.e., lower
doses of radiation therapy (RT) or chemotherapy
(CTX)) because of the unsubstantiated belief that they
will experience a larger number and more severe ad-
verse effects as well as poor functional outcomes and
significant decrements in quality of life (QOL) [8,9].
The foundations for these beliefs include the normal
physiological changes that occur with aging that could
influence drug metabolism, the co-occurrence of mul-
tiple co-morbidities in the elderly, and the increased
risk of adverse effects associated with polypharmacy
[2,10,11]. However, findings from studies on the impact
of co-morbidities and cancer treatment on older people
are contradictory [12-14].
In addition, in the limited number of studies that eval-
uated associations between age and the occurrence and
severity of physical and psychological symptoms, the
results are inconsistent. In a study of oncology patients
undergoing RT [15], sleep disturbance, pain, and distress
were significantly less prevalent among older patients
compared to younger patients, while shortness of breath
was significantly more prevalent among older patients
before RT. In another study of newly diagnosed cancer
patients [16], age was weakly correlated with ratings of
symptom distress (r = −0.11, p < 0.02) and older patients
reported lower levels of symptom distress. In contrast,
in a study of multiple symptoms [17], patients over
70 reported higher symptom distress scores than
patients less than 40 years of age. In a study of patients
with advanced cancer [10], compared to older patients,
younger patients reported higher pain severity scores
and better appetite. In terms of psychological symp-
toms, older age is consistently associated with lower
levels of psychological distress regardless of clinical fac-
tors [18-21]. However, less is known about how older
patients experience psychological distress associated
with cancer and its treatment [22,23].In both Australia and the United States, the number
of oncology patients over the age of 60 is growing
exponentially [1,24]. In fact, estimates suggest that by
2030, the incidence of cancer among older adults will in-
crease by 67% [25]. If research studies are not done to
characterize the symptom management needs of older
persons with cancer, the medical systems in both coun-
tries will not be prepared to provide the supportive care
interventions that these highly vulnerable patients need
in order to receive appropriate treatments and survive
their cancer. Therefore, given the paucity of research on
age-related differences in the multiple dimensions of the
symptom experience, the purpose of this study, using
the Memorial Symptom Assessment Scale (MSAS) [26],
was to evaluate for differences in ratings of symptom
occurrence, severity, frequency, and distress between
younger (< 60 years) and older (≥ 60 years) adults under-
going cancer treatment. Based on previous studies
[16,27-29], we hypothesized that older patients would
have significantly lower ratings on all symptom dimen-
sions than younger patients.
Methods
Study samples
Demographic, clinical, and symptom data from one
Australian study (i.e., Symptom Clusters) and two
United States studies (i.e., Fatigue, Pain, and Sleep Study
(FPS study), Symptom Prevalence Study) were com-
bined to conduct this analysis. All three studies enrolled
patients who were receiving active treatment for their
cancer. To evaluate the effect of age, patients were dichot-
omized into younger (< 60) and older (≥ 60) groups based
on cut-offs used in previous studies of cancer symptoms
[10,30,31], as well as findings that cancer mortality rates
are increasing in those > 60 years [1].
Symptom clusters study
This prospective, longitudinal study was designed to
identify symptom clusters and their effects on physical
and psychological functioning of patients with metastatic
disease. Data were collected from patients using an
interview-administered survey at the time of diagnosis
or progression of metastatic disease and again at 2
months and 4 months. Data from the first assessment
were used in these analyses.
Patients were recruited consecutively from two major
tertiary referral hospitals in Australia: the Royal Brisbane
and Women’s Hospital and Peter MacCallum Cancer
Centre (Melbourne). Patients were to participate if they:
were adults (> 18 years of age) who could read, write,
and understand English; had no cognitive limitations;
had a primary cancer of breast, lung, colon/rectum,
prostate, upper gastrointestinal tract, or ovaries; and
were diagnosed with metastatic disease in the past
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disease. Patients were excluded if they had local recur-
rence, but no evidence of metastatic disease; had a progno-
sis of < 4 months as determined by their clinician; or had
physical or cognitive impairments that precluded partici-
pation in the 15-minute survey. The study was approved
by the Ethics Committees of Queensland University of
Technology and the two participating hospitals.
Research staff liaised with clinical staff to identify
potentially eligible patients, using a standard screening
assessment sheet. All patients provided written consent
prior to completing the study questionnaires. Of 306
patients approached, 218 patients were recruited (71.2%
response rate). Reasons for non-participation included: a
clinician assessed that patients were not well enough to
participate (27.9%), prognosis < 4 months (22%), limited
English (18.7%), patient was currently participating in
another study (18.4%), and physically or cognitively un-
able to participate (13%). The questionnaire was com-
pleted during a 20 minute face-to-face interview
conducted by trained interviewers with nursing or
psychology backgrounds. Clinical and demographic data
were obtained from medical record reviews.
FPS study
This longitudinal study evaluated multiple symptoms in
patients who underwent primary or adjuvant RT. Patients
were recruited from two RT departments located in a
Comprehensive Cancer Center and a community-based
oncology program at the time of the patient’s simulation
visit. Patients were eligible to participate if they: were ≥ 18
years of age; were scheduled to receive primary or adju-
vant RT for one of four cancer diagnoses (i.e., breast,
prostate, lung, brain); were able to read, write, and under-
stand English; gave written informed consent; and had a
Karnofsky Performance Status (KPS) score of ≥ 60. Patients
were excluded if they had: metastatic disease, more than
one cancer diagnosis, or a diagnosed sleep disorder.
A total of 472 patients were approached and 185 con-
sented to participate (response rate of 34%). The primary
reasons for refusal were being overwhelmed or too busy.
The study was approved by the Committee on Human
Research at the University of California, San Francisco
(UCSF) and at the second site. At the time of the simu-
lation visit (i.e., approximately one week prior to the ini-
tiation of RT), patients were approached by a research
nurse to discuss participation in the study. After obtain-
ing written informed consent, patients completed the
study questionnaires. In addition, medical records were
reviewed for disease and treatment information.
Symptom prevalence study
This descriptive, cross-sectional study used self-report
questionnaires to obtain information from a conveniencesample of oncology outpatients. Patients were recruited
from four outpatient settings in Northern California, in-
cluding a university-based Cancer Center, a Veterans Affairs
facility, and two community-based outpatient clinics.
Patients were eligible to participate if they were > 18 years
of age; were able to read, write, and understand English;
gave written, informed consent; had KPS scores of ≥ 50;
and were receiving active cancer treatment.
A total of 310 patients were approached and 206 con-
sented to participate (response rate of 66%). The primary
reasons for refusal were that a patient was too ill to par-
ticipate (80%), too busy (15%), or not interested in the
research study (5%). Patients who agreed to participate
provided written informed consent and were given a
copy of the questionnaire booklet. They completed the
study questionnaires in their home and returned them
to the research office using a postage paid envelope. The
study was approved by the Committee on Human Re-
search at UCSF and at each of the study sites.
Instruments
Demographic and clinical characteristics
Demographic information on age, gender, marital status,
and living arrangements were obtained at enrollment.
Because of differences in the educational systems in
Australia and the United States, data on education were
recoded into a dichotomous variable (i.e., no post high
school versus post high school education). In addition,
patients’ medical records were reviewed for cancer
diagnosis, presence of metastatic disease, and current
treatment regimens (i.e., none, CTX, RT, or both CTX
and RT).
In the Australian study, patient’s functional status was
rated by their clinician using the Eastern Cooperative
Oncology Group (ECOG) Performance Status score that
ranges from 0 (fully active) to 4 (disabled) [32]. In the
United States studies, patients rated their functional
status using the KPS scale that ranged from 30 (I feel
severely disabled and need to be hospitalized) to 100
(I feel normal; I have no complaints or symptoms). The
KPS scale is widely used to evaluate functional status in
patients with cancer and has well established validity
and reliability. Based on the recommendations of Verger
and colleagues [33], the KPS scores were converted to
ECOG scores for use in subsequent analyses.
Memorial Symptom Assessment Scale (MSAS)
All three studies used the MSAS to evaluate the occur-
rence, severity, frequency, and distress of 32 symptoms
commonly associated with cancer and its treatment [26].
The MSAS is a self-report questionnaire designed to
measure the multidimensional experience of symptoms.
Using the MSAS, patients were asked to indicate
whether or not they had experienced each symptom in
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experienced the symptom, they were asked to rate its
frequency of occurrence, severity, and distress. Symptom
frequency was evaluated using a 4-point Likert scale
(i.e., 1 = rarely, 2 = occasionally, 3 = frequently, 4 = almost
constantly). Symptom severity was measured using a
4-point Likert scale (i.e., 1 = slight, 2 =moderate, 3 = se-
vere, 4 = very severe). Symptom distress was measured
using a 5-point Likert scale (i.e., 0 = not at all, 1 = a little
bit, 2 = somewhat, 3 = quite a bit, 4 = very much). Three
subscale scores (i.e., physical, psychological, global dis-
tress index) and a total MSAS score were calculated.
The reliability and validity of the MSAS is well estab-
lished in studies of oncology inpatients and outpatients
[26,34]. Cronbach’s alphas for the total sample, as well
as for patients < 60 years and ≥ 60 years are as follows:
physical subscale (.82, .82, .82), psychological subscale
(.81, .80, .77), global distress index (.82, .80, .83), and
total MSAS score (.88, .89, .87).
Analysis
The three data sets were combined and data were ana-
lyzed using SPSS version 19 and STATA SE Version 12.
Descriptive statistics, means, and standard deviations for
quantitative variables and frequencies and percentages
for categorical variables were generated to describe vari-
ous patient characteristics. Mean ratings of severity, fre-
quency, and distress were calculated for those patients
who reported the symptom. Because previous studies
have dichotomized older and younger patients at age 60
[10,30,31], older patients were defined as adults ≥ 60
years of age. Independent sample t-tests and Chi Square
analyses were used to evaluate for differences in demo-
graphic and clinical characteristics between the two age
groups. Differences between the two age groups in char-
acteristics with multiple levels (i.e., diagnosis, treatment,
ECOG Performance Status score) were further examined
using post-hoc contrasts with Bonferroni correction.
Logistic regression was used to evaluate the effect of
increasing age on the occurrence rates of each symp-
tom. Significant differences, between the two age groups
(< 60 (younger) and ≥ 60 (older) years of age), in the
occurrence rates of each symptom were evaluated
with binary logistic regression analyses. To examine the
differences between the two age groups in the severity,
frequency, and distress ratings of each symptom, ordinal
logistic regression was utilized. Significant differences,
between the two age groups (< 60 (younger) and ≥ 60
(older) years of age), in the MSAS subscale and total
scores were evaluated with linear regression analyses.
For all of the regression analyses, unadjusted and
adjusted values (e.g., odds ratios and their correspond-
ing 95% confidence intervals) were generated for each
symptom or scale score.Results
Differences in demographic and clinical characteristics
between older and younger patients
As shown in Table 1, data from 593 oncology outpati-
ents (i.e., 44.4% were < 60 years and 55.6% were ≥ 60
years of age) were evaluated. No differences were found
across the three studies, in the age distribution of
the patients. In addition, no differences were found,
across the three studies, in the mean age of the patients
(i.e., Symptom Clusters Study = 62.2 (± 12.0) years, FPS
Study = 60.8 (± 12.0) years, Symptom Prevalence
Study = 60.8 (± 12.4) years; F(2,590) = .994, p = .371).
Across the three studies, the age distribution in 10 year
increments was: 20 to 29 = 0.8%, 30 to 39 = 4.2%, 40 to
49 = 12.0%, 50 to 59 = 27.3%, 60 to 69 = 29.0%, 70 to
79 = 21.4%, and ≥ 80 = 5.3%.
The mean age of the entire sample was 61.3 (±12.1)
years. On average, younger patients were 50.3 (±7.7) and
older patients were 70.1 (±6.5) years of age (p < .001).
Older patients were: more likely to be male (p < .001);
less likely to have finished high school; more likely
to have prostate cancer (p < .001); more likely to be
receiving RT (p < .001), and more likely to be fully active
(p = .04).
Differences in symptom occurrence rates between older
and younger patients
Table 2 provides the symptom occurrence rates for the
total sample for each of the MSAS symptoms, as well as
the unadjusted and adjusted odds of symptom occur-
rence as age increases by one year. After controlling for
significant covariates (i.e., gender, education, diagnosis,
treatment, and ECOG performance status), as age
increased, significantly lower occurrence rates were
reported for difficulty concentrating, pain, feeling ner-
vous, nausea, difficulty sleeping, feeling bloated, vomit-
ing, feeling sad, sweats, worrying, problems with sexual
interest, feeling irritable, I don’t look like myself, and
changes in skin.
As shown in Table 3, after controlling for significant
covariates, differences in occurrence rates between the
two age groups were found for 15 (46.9%) of the 32
MSAS symptoms. Older patients reported significantly
lower occurrence rates for difficulty concentrating, pain,
feeling nervous, nausea, feeling drowsy, difficulty sleep-
ing, feeling bloated, vomiting, feeling sad, sweats, worry-
ing, problems with sexual interest, feeling irritable, I
don’t look like myself, and changes in skin.
Differences in symptom severity ratings between older
and younger patients
As shown in Table 4, after controlling for significant
covariates, differences in severity scores were found for
6 (18.9%) of the 32 MSAS symptoms. Older patients
Table 1 Demographic and clinical characteristics for the total sample and differences between younger (< 60, n = 263)
and older (≥ 60, n = 330) patients
Characteristic Total (%) Age group p-
value
Post hoc contrasts
< 60 (%) ≥ 60 (%) < 60 (%) ≥ 60 (%) p-value
Study project
Fatigue, Pain, and Sleep 28.8 28.9 28.8 .170
Symptom Prevalence 34.4 38.0 31.5
Symptom Clusters 36.8 33.1 39.7
Gender- Female 54.6 70.7 41.8 < .001
Lives alone 26.4 24.0 28.2 .260
Partnered/married 60.9 57.3 63.7 .126
Education – Post high school 61.4 68.8 55.5 .001
Diagnosis
Breast 33.6 48.3 21.8 48.3 21.8 .0125
Prostate 26.0 11.0 37.9 < .001 11.0 37.9 .0125
Lung 13.2 11.4 14.5
Other 27.3 29.3 25.8
Metastases 34.9 37.3 32.9 .297
Treatment
None 15.5 13.3 17.3
Only radiation 43.6 33.8 51.4 < .001 33.8 51.4 .0125
Only chemotherapy 27.4 31.2 24.3
Both 13.5 21.7 7.0 21.7 7.0 .0125
ECOG Performance Status
Fully active 21.4 15.8 26.0 15.8 26.0 .0100
Ambulatory, light work 48.9 53.1 45.5 .043
Ambulatory, mobile > 50% 21.6 23.5 20.1
Ambulatory, mobile < 50% 7.2 6.5 7.7
Disabled 0.9 1.2 0.6
Age (years; mean (standard deviation)) 61.3 (12.1) 50.3 (7.7) 70.1 (6.5) < .001
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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mouth, feeling drowsy, feeling sad, sweats, worrying, and
I don’t look like myself.
Differences in symptom frequency ratings between older
and younger patients
As shown in Table 5, after controlling for significant
covariates, differences in frequency scores were found
for 4 (12.5%) of the 32 MSAS symptoms. Older patients
reported significantly lower frequency scores for feeling
nervous, dry mouth, nausea, and feeling bloated.
Differences in symptom distress ratings between older
and younger patients
As shown in Table 6, after controlling for significant
covariates, differences in distress scores were found for
14 (43.8%) of the 32 MSAS symptoms. Older patients
reported significantly lower distress scores for pain, lack
of energy, cough, dry mouth, nausea, feeling drowsy,difficulty sleeping, feeling bloated, feeling sad, sweats,
worrying, hair loss, I don’t look like myself, and changes
in skin.
Differences in MSAS subscale and total scores between
younger and older patients
As shown in Table 7, after controlling for significant
covariates, older patients reported significantly lower
scores on all of the MSAS subscales, as well as on the
MSAS total score.
Differences in rankings of symptoms with highest
occurrence, severity, frequency, and distress ratings
between older and younger patients
Table 8 provides a summary of the differences in the
rankings of the various symptom dimensions (i.e., occur-
rence, severity, frequency, distress) for the top 10 symp-
toms between older and younger patients. For symptom
occurrence, the four most prevalent symptoms (i.e., lack





Unadjusted values Adjusted values
Continuous age Continuous age
Odds ratio CI Odds ratio CI
Difficulty concentrating 45.9 .96+ .95-.97 .97+ .96-.99
Pain 64.1 .97+ .96-.98 .97** .96-.99
Lack of energy 74.7 .98** .96-.99 .99 .97-1.01
Cough 37.6 1.00 .98-1.01 1.00 .98-1.02
Feeling nervous 32.4 .98** .96-.99 .98* .97-.99
Dry mouth 42.8 1.00 .99-1.01 1.01 .99-1.03
Nausea 31.2 .98** .97-.99 .98* .97-.99
Feeling drowsy 58.7 .99 .97-1.00 .99 .98-1.01
Numbness/tingling in hands/feet 31.9 .99 .97-1.00 .99 .98-1.01
Difficulty sleeping 53.3 .96+ .95-.98 .97** .96-.99
Feeling bloated 24.8 .97+ .95-.98 .97+ .95-.98
Problems with urination 29.5 1.03+ 1.02-1.05 1.01 .99-1.03
Vomiting 13.8 .98* .97-.99 .97* .95-.99
Shortness of breath 34.6 .99 .98-1.00 .99 .97-1.00
Diarrhea 21.8 1.00 .99-1.02 1.00 .98-1.02
Feeling sad 40.5 .95+ .94-.97 .96+ .94-.97
Sweats 37.4 .98** .96-.99 .98* .96-.99
Worrying 43.5 .95+ .94-.96 .95+ .94-.97
Problems with sexual interest 28.3 .97+ .95-.98 .95+ .93-.97
Itching 28.0 .98* .97-.99 .99 .98-1.01
Lack of appetite 33.9 .99 .97-1.00 .99 .98-1.01
Dizziness 23.8 .99 .98-1.01 .99 .98-1.01
Difficulty swallowing 15.7 1.00 .98-1.02 1.00 .98-1.02
Feeling irritable 40.8 .96+ .95-.97 .96+ .95-.98
Mouth sores 13.7 1.00 .98-1.02 1.01 .99-1.03
Changes in the way food tastes 30.5 1.00 .99-1.02 1.01 .99-1.03
Weight loss 23.1 .99 .98-1.01 1.00 .98-1.02
Hair loss 20.7 .98* .97-.99 .99 .97-1.01
Constipation 32.2 1.00 .99-1.01 1.00 .98-1.01
Swelling of arms or legs 16.4 1.01 .99-1.03 1.02 1.00-1.04
I don’t look like myself 27.3 .97+ .95-.98 .98* .96-.99
Changes in skin 28.2 .96+ .94-.97 .98** .96-.99
Abbreviation: CI, confidence interval.
*p < .05, **p < .01, +p < .001.
Cataldo et al. BMC Cancer 2013, 13:6 Page 6 of 16
http://www.biomedcentral.com/1471-2407/13/6of energy, pain, feeling drowsy, difficulty sleeping) were
the same for both age groups. Eight of 10 symptoms
(80%) were in the top 10 for both age groups. Feeling
sad and sweats were unique to younger patients. Pro-
blems with urination, cough, and shortness of breath
were unique to older patients.
For symptom severity, the four most severe symptoms
(i.e., problems with sexual interest, hair loss, constipa-
tion, difficulty sleeping) were the same for both age
groups. Seven of 10 symptoms (70%) were in the top 10
for both age groups. Sweats, I don’t look like myself, and
worrying were unique to younger patients. Problemswith urination, shortness of breath, and lack of appetite
were unique to older patients.
For symptom frequency, the three most frequent
symptoms (i.e., problems with sexual interest, hair loss,
lack of energy) were the same for both age groups. Seven
of 10 symptoms (70%) were in the top 10 for both age
groups. Dry mouth, I don’t look like myself, and changes
in skin were unique to younger patients. Problems with
urination, lack of appetite, and changes in taste were
unique to older patients.
For symptom distress, two symptoms (i.e., problems
with sexual interest, constipation) were ranked as the
Table 3 Differences in symptom OCCURRENCE rates between younger (< 60, n = 263) and older (≥ 60, n = 330) patients
Symptom Occurrence rates
(%) by age group
Unadjusted values Adjusted values
Older age Older age
<60 ≥60 Odds ratio CI Odds ratio CI
Difficulty concentrating 57.0 37.0 .44+ .32-.62 .58** .40-.85
Pain 73.0 57.0 .49+ .35-.69 .51** .34-.75
Lack of energy 81.7 69.1 .50+ .34-.74 .69 .44-1.08
Cough 40.3 35.5 .81 .58-1.14 .89 .60-1.32
Feeling nervous 39.5 26.7 .56** .39-.79 .61* .41-.91
Dry mouth 43.7 42.1 .94 .68-1.30 1.10 .75-1.62
Nausea 38.0 25.8 .57** .40-.80 .52** .34-.79
Feeling drowsy 65.0 53.6 .62** .45-.87 .68* .47-.99
Numbness/tingling in hands/feet 36.1 28.5 .70* .50-.99 .76 .51-1.14
Difficulty sleeping 63.9 44.8 .46+ .33-.64 .55** .38-.80
Feeling bloated 31.9 19.1 .50+ .35-.73 .51** .33-.78
Problems with urination 21.3 36.1 2.09+ 1.44-3.02 1.18 .76-1.83
Vomiting 17.5 10.9 .58* .36-.92 .41** .23-.72
Shortness of breath 37.6 32.1 .78 .56-1.10 .73 .48-1.11
Diarrhea 21.7 21.8 1.01 .68-1.49 .86 .54-1.35
Feeling sad 52.1 31.2 .42+ .30-.58 .46+ .31-.67
Sweats 45.2 31.2 .55+ .39-.77 .60** .41-.88
Worrying 57.8 32.1 .35+ .25-.48 .39+ .27-.56
Problems with sexual interest 35.7 22.4 .52+ .36-.75 .34+ .22-54
Itching 34.2 23.0 .58** .40-.83 .72 .47-1.08
Lack of appetite 38.0 30.6 .72 .51-1.01 .68 .45-1.02
Dizziness 27.0 21.2 .73 .50-1.06 .71 .46-1.10
Difficulty swallowing 16.3 15.2 .91 .59-1.43 .92 .55-1.56
Feeling irritable 51.7 32.1 .44+ .32-.62 .47+ .32-.69
Mouth sores 14.8 12.7 .84 .52-1.34 .91 .54-1.54
Changes in the way food tastes 31.2 30.0 .95 .67-1.34 1.09 .71-1.68
Weight loss 23.2 23.0 .99 .68-1.46 1.10 .69-1.73
Hair loss 23.6 18.5 .74 .49-1.09 .90 .55-1.49
Constipation 33.8 30.9 .87 .62-1.24 .82 .55-1.22
Swelling of arms or legs 16.3 16.4 1.00 .65-1.55 1.10 .66-1.82
I don’t look like myself 35.4 20.9 .48+ .34-.70 .64* .42-.98
Changes in skin 38.0 20.3 .42+ .29-.60 .62* .41-.94
Abbreviation: CI, confidence interval.
*p < .05, **p < .01, +p < .001.
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groups. Six of 10 symptoms (60%) were in the top 10 for
both age groups. Nausea, feeling bloated, feeling sad,
and I don’t look like myself were unique to younger
patients. Problems with urination, shortness of breath,
difficulty swallowing, and swelling of arms or legs were
unique to older patients.
Discussion
This study is the first to evaluate for differences in mul-
tiple dimensions of the symptom experience (i.e., occur-
rence, severity, frequency, and distress) between older andyounger adults undergoing active treatment for cancer.
The majority of the age differences were found in ratings
of symptom occurrence with older patients reporting sig-
nificantly lower occurrence rates for 15 (46.9%) of the
MSAS symptoms. While fewer age-related differences
were found in ratings of symptom severity, frequency, and
distress, for younger and older patients who reported a
specific symptom, a similar pattern was found across all
three dimensions, namely when differences occurred older
patients reported significantly lower ratings.
While this secondary analysis provides interesting and
important data on age-related differences in various







Severity ratings† (%) Unadjusted values Adjusted values
Older age Older age
1 2 3 4 OR CI p-value OR CI p-value
Difficulty concentrating 149 <60 1.67 44.3 45.0 10.1 0.7 .80 .50-1.28 .353 .78 .46-1.32 .354
115 ≥60 1.61 50.4 40.0 7.8 1.7
Pain 192 <60 2.08 24.5 47.9 22.9 4.7 1.08 .74-1.58 .674 .97 .64-1.49 .898
181 ≥60 2.12 24.3 45.3 24.3 6.1
Lack of energy 214 <60 2.15 15.4 57.5 23.8 3.3 .91 .64-1.31 .622 .81 .55-1.21 .311
217 ≥60 2.13 21.7 49.8 22.1 6.5
Cough 102 <60 1.74 46.1 36.3 15.7 2.0 1.04 .63-1.73 .870 .86 .47-1.55 .609
110 ≥60 1.75 44.5 38.2 14.5 2.7
Feeling nervous 103 <60 1.83 35.9 47.6 13.6 2.9 .81 .47-1.40 .452 .81 .42-1.54 .514
85 ≥60 1.78 40.0 48.2 5.9 5.9
Dry mouth 110 <60 2.06 28.2 41.8 25.5 4.5 .64 .40-1.03 .068 .54 .32-.91 .020
131 ≥60 1.89 38.2 41.2 14.5 6.1
Nausea 99 <60 1.99 31.3 42.4 22.2 4.0 .64 .37-1.10 .107 .62 .33-1.14 .123
81 ≥60 1.80 43.2 37.0 16.0 3.7
Feeling drowsy 167 <60 1.95 24.6 58.1 15.6 1.8 .68 .45-1.03 .068 .61 .38-.96 .033
169 ≥60 1.82 32.5 55.0 10.7 1.8
Numbness/tingling in hands/feet 94 <60 1.85 36.2 45.7 14.9 3.2 .90 .53-1.55 .710 .79 .42-1.52 .484
91 ≥60 1.85 41.8 38.5 13.2 6.6
Difficulty sleeping 168 <60 2.23 14.9 54.8 23.2 7.1 .87 .56-1.33 .512 .67 .42-1.09 .108
141 ≥60 2.16 17.0 54.6 24.1 4.3
Feeling bloated 82 <60 1.91 30.5 51.2 14.6 3.7 .77 .40-1.47 .429 .77 .36-1.66 .510
55 ≥60 1.82 36.4 49.1 10.9 3.6
Problems with urination 54 <60 1.96 33.3 42.6 18.5 5.6 1.14 .61-2.11 .685 1.10 .56-2.18 .777
110 ≥60 2.01 26.4 52.7 14.5 6.4
Vomiting 43 <60 1.91 41.9 32.6 18.6 7.0 .90 .38-2.14 .811 .51 .17-1.54 .232
29 ≥60 1.79 37.9 44.8 17.2 0.0
Shortness of breath 97 <60 1.78 40.2 45.4 10.3 4.1 1.52 .90-2.58 .116 1.27 .71-2.29 .423
99 ≥60 2.00 33.3 42.4 15.2 9.1
Diarrhea 54 <60 1.93 24.1 61.1 13.0 1.9 .67 .33-1.35 .263 .62 .27-1.42 .258
63 ≥60 1.81 36.5 49.2 11.1 3.2
Feeling sad 137 <60 1.99 30.7 43.8 21.2 4.4 .43 .26-.72 .001 .43 .24-.76 .003
93 ≥60 1.66 46.2 46.2 3.2 4.3
Sweats 117 <60 2.14 23.9 44.4 25.6 6.0 .54 .33-.91 .019 .56 .31-.997 .049
95 ≥60 1.86 34.7 46.3 16.8 2.1
Worrying 152 <60 2.10 20.4 58.6 11.8 9.2 .43 .26-.72 .001 .52 .30-.90 .020
101 ≥60 1.77 38.6 49.5 7.9 4.0
Problems with sexual interest 92 <60 2.50 22.8 31.5 18.5 27.2 1.43 .82-2.52 .212 1.12 .57-2.19 .745
69 ≥60 2.72 18.8 24.6 21.7 34.8
Itching 88 <60 1.86 38.6 43.2 11.4 6.8 .84 .46-1.52 .562 .89 .46-1.75 .745
69 ≥60 1.78 42.0 43.5 8.7 5.8
Lack of appetite 99 <60 2.00 27.3 49.5 19.2 4.0 .96 .57-1.64 .886 .77 .42-1.43 .409
94 ≥60 2.00 27.7 51.1 14.9 6.4
Dizziness 69 <60 1.54 55.1 37.7 5.8 1.4 .84 .43-1.65 .615 .61 .27-1.39 .241
64 ≥60 1.48 59.4 34.4 4.7 1.6
Difficulty swallowing 40 <60 2.03 27.5 45.0 25.0 2.5 .53 .23-1.21 .133 .39 .14-1.10 .074
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Frequency ratings† (%) Unadjusted values Adjusted values
Older age Older age
1 2 3 4 OR CI p-value OR CI p-value
Difficulty concentrating 150 <60 2.19 22.7 44.0 25.3 8.0 .78 .50-1.21 .269 .76 .46-1.25 .277
122 ≥60 2.08 24.6 50.8 16.4 8.2
Pain 192 <60 2.64 13.0 33.3 30.2 23.4 .96 .67-1.38 .829 .95 .63-1.44 .825
188 ≥60 2.62 14.9 32.4 28.7 23.9
Lack of energy 215 <60 2.82 5.1 30.2 42.3 22.3 .88 .62-1.23 .446 .77 .53-1.13 .179
228 ≥60 2.74 10.5 32.0 30.3 27.2
Cough 106 <60 2.12 26.4 41.5 25.5 6.6 .98 .61-1.59 .937 .72 .42-1.25 .246
117 ≥60 2.12 26.5 42.7 23.1 7.7
Feeling nervous 104 <60 2.13 22.1 48.1 24.0 5.8 .57 .33-.97 .038 .52 .27-.99 .046
88 ≥60 1.92 35.2 45.5 11.4 8.0
Dry mouth 115 <60 2.66 13.9 26.1 40.0 20.0 .66 .42-1.03 .070 .52 .32-.85 .009
139 ≥60 2.44 20.9 31.7 30.2 17.3
Nausea 100 <60 2.23 23.0 40.0 28.0 9.0 .55 .32-.94 .028 .54 .29-.99 .047
85 ≥60 1.95 34.1 43.5 15.3 7.1
Feeling drowsy 171 <60 2.40 11.7 44.4 36.3 7.6 .82 .56-1.22 .338 .65 .42-1.01 .058
176 ≥60 2.34 11.9 52.3 25.6 10.2
Numbness/tingling in hands/feet 95 <60 2.63 16.8 36.8 12.6 33.7 1.08 .65-1.81 .771 .94 .52-1.72 .846
94 ≥60 2.68 20.2 23.4 24.5 31.9
Difficulty sleeping 168 <60 2.70 9.5 32.1 37.5 20.8 .88 .59-1.32 .541 .64 .41-1.02 .058
147 ≥60 2.63 9.5 32.7 42.9 15.0
Feeling bloated 84 <60 2.39 22.6 32.1 28.6 16.7 .54 .29-.98 .042 .49 .24-.99 .046
Table 4 Differences in SEVERITY ratings between younger (< 60, n = 263) and older (≥ 60, n = 330) patients (Continued)
43 ≥60 1.79 37.2 51.2 7.0 4.7
Feeling irritable 135 <60 1.77 40.7 42.2 16.3 0.7 .82 .50-1.34 .425 .65 .37-1.15 .142
98 ≥60 1.68 41.8 49.0 8.2 1.0
Mouth sores 37 <60 1.86 43.2 35.1 13.5 8.1 .55 .23-1.34 .188 .52 .19-1.43 .205
35 ≥60 1.60 60.0 22.9 14.3 2.9
Change in way food tastes 79 <60 2.06 27.8 48.1 13.9 10.1 .81 .46-1.43 .476 1.05 .57-1.93 .883
91 ≥60 1.96 31.9 47.3 14.3 6.6
Weight loss 60 <60 1.67 48.3 38.3 11.7 1.7 .87 .45-1.69 .674 .60 .28-1.30 .196
67 ≥60 1.63 52.2 35.8 9.0 3.0
Hair loss 61 <60 2.38 27.9 26.2 26.2 19.7 .97 .50-1.88 .921 .77 .36-1.61 .482
52 ≥60 2.37 32.7 23.1 19.2 25.0
Constipation 87 <60 2.38 17.2 40.2 29.9 12.6 .67 .39-1.14 .139 .74 .42-1.32 .308
96 ≥60 2.19 24.0 43.8 21.9 10.4
Swelling of arms or legs 42 <60 2.19 33.3 31.0 19.0 16.7 .92 .43-1.98 .837 .86 .36-2.04 .734
47 ≥60 2.09 25.5 44.7 25.5 4.3
I don’t look like myself 91 <60 2.14 24.2 47.3 18.7 9.9 .52 .28-.95 .033 .49 .25-.96 .037
62 ≥60 1.82 43.5 32.3 22.6 1.6
Changes in skin 99 <60 2.07 24.2 53.5 13.1 9.1 .63 .34-1.16 .140 .80 .41-1.56 .510
61 ≥60 1.89 37.7 42.6 13.1 6.6
Abbreviations: CI, confidence interval; OR, odds ratio.
†Severity ratings = slight (1), moderate (2), severe (3), very severe (4).
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Table 5 Differences in FREQUENCY ratings between younger (< 60, n = 263) and older (≥ 60, n = 330) patients
(Continued)
63 ≥60 2.06 28.6 47.6 12.7 11.1
Problems with urination 56 <60 2.39 21.4 33.9 28.6 16.1 1.52 .84-2.73 .164 1.29 .68-2.46 .438
119 ≥60 2.61 11.8 33.6 37.0 17.6
Vomiting 46 <60 1.87 39.1 41.3 13.0 6.5 .85 .38-1.93 .705 .46 .15-1.38 .165
36 ≥60 1.81 44.4 36.1 13.9 5.6
Shortness of breath 99 <60 2.17 19.2 52.5 20.2 8.1 1.30 .78-2.14 .311 .97 .55-1.70 .916
106 ≥60 2.35 25.5 34.0 20.8 19.8
Diarrhea 57 <60 2.12 22.8 47.4 24.6 5.3 .56 .29-1.10 .094 .47 .21-1.03 .059
72 ≥60 1.89 29.2 55.6 12.5 2.8
Feeling sad 137 <60 2.05 28.5 42.3 24.8 4.4 .99 .62-1.59 .978 .79 .46-1.36 .386
103 ≥60 2.08 27.2 47.6 15.5 9.7
Sweats 119 <60 2.39 16.8 37.0 36.1 10.1 .66 .41-1.07 .093 .64 .37-1.12 .121
103 ≥60 2.21 22.3 44.7 22.3 10.7
Worrying 152 <60 2.41 9.9 52.0 25.0 13.2 .59 .36-.94 .028 .63 .37-1.08 .094
106 ≥60 2.20 22.6 48.1 16.0 13.2
Problems with sexual interest 93 <60 2.86 15.1 23.7 21.5 39.8 1.07 .61-1.86 .821 1.04 .53-2.02 .916
74 ≥60 2.89 17.6 17.6 23.0 41.9
Itching 90 <60 2.38 14.4 46.7 25.6 13.3 .72 .41-1.27 .254 .71 .38-1.33 .289
76 ≥60 2.21 23.7 40.8 26.3 9.2
Lack of appetite 100 <60 2.44 18.0 39.0 24.0 19.0 1.44 .88-2.38 .149 1.16 .66-2.05 .598
101 ≥60 2.64 18.8 24.8 29.7 26.7
Dizziness 71 <60 1.82 39.4 40.8 18.3 1.4 .96 .52-1.78 .902 .78 .38-1.61 .502
70 ≥60 1.81 38.6 45.7 11.4 4.3
Difficulty swallowing 43 <60 2.23 30.2 32.6 20.9 16.3 .87 .41-1.81 .701 .56 .23-1.38 .207
50 ≥60 2.14 32.0 34.0 22.0 12.0
Feeling irritable 136 <60 1.99 30.1 44.1 22.1 3.7 .78 .48-1.25 .300 .67 .38-1.17 .161
105 ≥60 1.88 33.3 47.6 17.1 1.9
Mouth sores 39 <60 2.21 38.5 28.2 7.7 25.6 .73 .33-1.63 .447 .75 .29-1.93 .553
42 ≥60 2.02 47.6 23.8 7.1 21.4
Change in way food tastes 80 <60 2.54 17.5 31.3 31.3 20.0 1.11 .65-1.88 .709 1.16 .65-2.08 .616
98 ≥60 2.60 16.3 33.7 23.5 26.5
Weight loss 59 <60 2.07 22.0 55.9 15.3 6.8 .76 .40-1.44 .400 .56 .27-1.16 .120
75 ≥60 1.99 34.7 41.3 14.7 9.3
Hair loss 62 <60 2.85 16.1 22.6 21.0 40.3 1.02 .53-1.95 .953 .89 .43-1.84 .745
60 ≥60 2.85 21.7 15.0 20.0 43.3
Constipation 89 <60 2.53 14.6 40.4 22.5 22.5 .82 .49-1.38 .455 .87 .49-1.53 .626
102 ≥60 2.42 15.7 45.1 20.6 18.6
Swelling of arms or legs 43 <60 2.67 23.3 23.3 16.3 37.2 1.04 .51-2.15 .906 .91 .39-2.12 .832
54 ≥60 2.70 24.1 20.4 16.7 38.9
I don’t look like myself 92 <60 2.67 15.2 29.3 28.3 27.2 .79 .45-1.39 .420 .84 .45-1.57 .587
69 ≥60 2.54 20.3 27.5 30.4 21.7
Changes in skin 100 <60 2.77 15.0 24.0 30.0 31.0 .69 .39-1.20 .188 .97 .52-1.82 .929
67 ≥60 2.54 23.9 25.4 23.9 26.9
Abbreviations: CI, confidence interval; OR, odds ratio.
†Frequency ratings = rarely (1), occasionally (2), frequently (3), almost constantly (4).
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Distress ratings† (%) Unadjusted values Adjusted values
Older age Older age
0 1 2 3 4 OR CI p-value OR CI p-value
Difficulty concentrating 147 <60 1.52 17.7 38.1 22.4 18.4 3.4 .71 .45-1.10 .124 .82 .50-1.34 .424
116 ≥60 1.33 25.0 37.9 21.6 10.3 5.2
Pain 192 <60 2.01 6.3 32.3 29.2 19.3 13.0 .63 .43-.90 .012 .65 .43-.98 .041
183 ≥60 1.69 15.8 32.2 26.2 18.0 7.7
Lack of energy 212 <60 2.04 8.5 26.4 30.2 22.6 12.3 .54 .39-.77 <.001 .57 .39-.83 .004
220 ≥60 1.64 20.5 30.5 22.3 18.6 8.2
Cough 103 <60 1.39 29.1 28.2 24.3 11.7 6.8 .60 .37-.97 .037 .52 .29-.91 .022
112 ≥60 1.07 42.9 25.0 19.6 7.1 5.4
Feeling nervous 102 <60 1.70 10.8 38.2 26.5 19.6 4.9 .51 .30-.87 .013 .57 .30-1.06 .075
85 ≥60 1.33 23.5 40.0 22.4 8.2 5.9
Dry mouth 111 <60 1.45 22.5 37.8 20.7 9.9 9.0 .50 .32-.80 .003 .47 .29-.76 .002
133 ≥60 1.05 42.1 29.3 15.8 7.5 5.3
Nausea 99 <60 1.84 12.1 32.3 29.3 12.1 14.1 .47 .27-.80 .006 .46 .25-.86 .015
81 ≥60 1.37 33.3 29.6 13.6 13.6 9.9
Feeling drowsy 165 <60 1.39 21.2 39.4 23.0 12.1 4.2 .53 .36-.79 .002 .52 .34-.80 .003
167 ≥60 1.07 40.1 31.7 13.8 9.6 4.8
Numbness/tingling in hands/feet 94 <60 1.40 21.3 39.4 20.2 16.0 3.2 .72 .43-1.21 .212 .84 .46-1.56 .586
91 ≥60 1.25 33.0 33.0 16.5 11.0 6.6
Difficulty sleeping 166 <60 2.01 9.6 29.5 25.9 19.9 15.1 .61 .41-.92 .017 .54 .35-.86 .008
142 ≥60 1.66 19.0 27.5 29.6 16.2 7.7
Feeling bloated 81 <60 1.85 16.0 24.7 27.2 22.2 9.9 .43 .23-.81 .008 .38 .18-.80 .011
56 ≥60 1.30 19.6 42.9 26.8 8.9 1.8
Problems with urination 54 <60 1.57 24.1 25.9 25.9 16.7 7.4 1.21 .67-2.19 .530 .91 .47-1.76 .783
108 ≥60 1.70 14.8 32.4 31.5 10.2 11.1
Vomiting 43 <60 1.63 23.3 32.6 16.3 14.0 14.0 .78 .34-1.79 .553 .58 .21-1.62 .298
30 ≥60 1.43 33.3 20.0 26.7 10.0 10.0
Shortness of breath 97 <60 1.63 14.4 41.2 21.6 12.4 10.3 .79 .48-1.30 .347 .80 .46-1.39 .427
100 ≥60 1.47 28.0 26.0 24.0 15.0 7.0
Diarrhea 54 <60 1.59 18.5 38.9 14.8 20.4 7.4 .69 .36-1.34 .274 .61 .28-1.31 .204
63 ≥60 1.32 25.4 33.3 30.2 6.3 4.8
Feeling sad 137 <60 1.87 8.0 36.5 27.0 17.5 10.9 .47 .29-.77 .003 .49 .28-.85 .011
94 ≥60 1.41 14.9 46.8 24.5 9.6 4.3
Sweats 117 <60 1.75 17.1 29.1 28.2 12.8 12.8 .49 .30-.80 .005 .56 .32-.98 .040
95 ≥60 1.26 24.2 40.0 24.2 8.4 3.2
Worrying 151 <60 1.93 7.3 34.4 28.5 17.9 11.9 .45 .28-.72 .001 .57 .34-.96 .033
101 ≥60 1.46 8.9 53.5 23.8 10.9 3.0
Problems with sexual interest 91 <60 2.08 22.0 19.8 15.4 14.3 28.6 .96 .55-1.66 .875 .89 .46-1.73 .731
69 ≥60 2.03 18.8 20.3 24.6 11.6 24.6
Itching 88 <60 1.56 15.9 40.9 25.0 8.0 10.2 .82 .46-1.45 .497 1.04 .55-1.95 .908
69 ≥60 1.42 24.6 31.9 27.5 8.7 7.2
Lack of appetite 99 <60 1.38 27.3 31.3 24.2 10.1 7.1 .85 .51-1.41 .529 .85 .48-1.51 .589
96 ≥60 1.28 32.3 29.2 21.9 11.5 5.2
Dizziness 69 <60 1.32 23.2 37.7 26.1 10.1 2.9 .84 .45-1.56 .572 .62 .30-1.29 .202
63 ≥60 1.25 23.8 46.0 15.9 9.5 4.8
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Table 6 Differences in DISTRESS ratings between younger (< 60, n = 263) and older (≥ 60, n = 330) patients (Continued)
Difficulty swallowing 40 <60 1.65 10.0 40.0 30.0 15.0 5.0 .96 .44-2.09 .924 .85 .35-2.06 .724
43 ≥60 1.63 20.9 27.9 23.3 23.3 4.7
Feeling irritable 135 <60 1.49 21.5 34.8 24.4 11.9 7.4 .79 .49-1.27 .335 .82 .48-1.42 .485
96 ≥60 1.31 18.8 47.9 17.7 14.6 1.0
Mouth sores 36 <60 1.67 22.2 30.6 19.4 13.9 13.9 .46 .20-1.09 .079 .41 .16-1.03 .058
35 ≥60 1.11 31.4 42.9 11.4 11.4 2.9
Change in way food tastes 78 <60 1.69 17.9 32.1 25.6 11.5 12.8 .47 .27-.81 .007 .57 .31-1.05 .072
89 ≥60 1.18 32.6 36.0 14.6 14.6 2.2
Weight loss 61 <60 1.05 45.9 26.2 13.1 6.6 8.2 .67 .35-1.29 .232 .51 .24-1.09 .082
68 ≥60 0.78 54.4 26.5 8.8 7.4 2.9
Hair loss 61 <60 1.74 19.7 29.5 21.3 16.4 13.1 .50 .26-.97 .041 .48 .23-.99 .048
55 ≥60 1.29 43.6 20.0 9.1 18.2 9.1
Constipation 87 <60 2.09 13.8 23.0 25.3 16.1 21.8 .68 .41-1.14 .145 .74 .42-1.29 .285
95 ≥60 1.80 23.2 25.3 15.8 20.0 15.8
Swelling of arms or legs 42 <60 1.64 28.6 23.8 19.0 11.9 16.7 .96 .46-2.01 .913 1.11 .46-2.67 .819
48 ≥60 1.58 27.1 25.0 18.8 20.8 8.3
I don’t look like myself 91 <60 1.89 11.0 36.3 19.8 18.7 14.3 .32 .17-.58 <.001 .30 .15-.58 <.001
64 ≥60 1.14 34.4 34.4 17.2 10.9 3.1
Changes in skin 99 <60 1.76 11.1 36.4 29.3 12.1 11.1 .41 .23-.76 .004 .51 .27-.98 .043
62 ≥60 1.26 38.7 24.2 17.7 11.3 8.1
Abbreviations: CI, confidence interval; OR, odds ratio.
†Distress ratings = not at all (0), a little bit (1), somewhat (2), quite a bit (4), very much (5).
Cataldo et al. BMC Cancer 2013, 13:6 Page 12 of 16
http://www.biomedcentral.com/1471-2407/13/6dimensions of the symptom experience in a very large
sample of oncology patients, several limitations need to
be acknowledged before our findings are placed within
the context of an extremely limited literature. First,
detailed information was not available on the exact num-
ber or specific types of comorbidities these patients
experienced. In addition, specific details on the doses of
CTX and RT received by these patients were not col-
lected for these studies. Despite these limitations, find-
ings from this initial analysis can be used to generate
testable hypotheses for future research.
For almost 50% of the MSAS symptoms, older patients
reported significantly lower occurrence rates. However,
eight of the eleven symptoms with the highest occur-
rence rates were identical in the two age groups (i.e.,
lack of energy, pain, feeling drowsy, difficulty sleeping,
dry mouth, difficulty concentrating, worrying, feelingTable 7 Differences in subscale and total scores on the Memo
(< 60, n = 263) and older (≥ 60, n = 330) patients
Scale Unadjusted scores
Mean (Standard deviation)
< 60 years ≥ 60 years
Physical subscale .92 (.63) .70 (.58)
Psychological subscale 1.15 (.84) .67 (.69)
Global Distress Index 1.17 (.74) .78 (.70)
Total MSAS score .84 (.50) .60 (.46)irritable). Consistent with previous studies of multiple
symptoms [15,35-39], these eight symptoms are among
the most common symptoms reported by oncology
patients regardless of cancer diagnosis, stage of disease,
and/or cancer treatment. Since these eight symptom
occurrence rates exhibit a similar distribution pattern in
both age groups, one plausible hypothesis for the signifi-
cantly lower occurrence rates for six of these symptoms
in older patients (no difference in lack of energy or dry
mouth) is that older patients received lower doses of
CTX or RT [3,12,14,40]. An equally plausible hypothesis
is that older patients received comparable doses of ther-
apy. However, because of age-related changes in a num-
ber of biological processes [41] and/or a variety of
psychosocial factors [42,43], older patients reported
lower symptom occurrence rates. For example, age-
related changes may occur in the hypothalamic-adrenal-rial Symptom Assessment Scale (MSAS) between younger
Adjusted scores
Mean (Standard error)
p-value < 60 years ≥ 60 years p-value
<.0001 .90 (.04) .70 (.03) <.0001
<.0001 1.10 (.05) .70 (.04) <.0001
<.0001 1.13 (.04) .81 (.04) <.0001
<.0001 .81 (.03) .60 (.03) <.0001
Table 8 Differences between younger (< 60, n = 263) and
older (≥ 60, n = 330) patients in rankings of symptoms
with the highest occurrence, severity, frequency, and
distress ratings
OCCURRENCE RATINGS





1 Lack of energy 81.7 Lack of energy 69.1
2 Pain 73.0 Pain 57.0
3 Feeling drowsy 65.0 Feeling drowsy 53.6
4 Difficulty sleeping 63.9 Difficulty sleeping 44.8






7 Feeling sad 52.1 Problems with
urination
36.1
8 Feeling irritable 51.7 Cough 35.5
9 Sweats 45.2 Shortness of breath 32.1







1 Problems with sexual
interest
2.50 Problems with sexual
interest
2.72
2 Hair loss 2.38 Hair loss 2.37
3 Constipation 2.38 Constipation 2.19
4 Difficulty sleeping 2.23 Difficulty sleeping 2.16
5 Swelling of arms or
legs
2.19 Lack of energy 2.13
6 Lack of energy 2.15 Pain 2.12
7 Sweats 2.14 Swelling of arms or
legs
2.09





9 Worrying 2.10 Shortness of breath 2.00






1 Problems with sexual
interest
2.86 Problems with sexual
interest
2.89
2 Hair loss 2.85 Hair loss 2.85
3 Lack of energy 2.82 Lack of energy 2.74
4 Changes in skin 2.77 Swelling of arms or
legs
2.70
5 Difficulty sleeping 2.70 Numbness/tingling
in hands/feet
2.68
6 Swelling of arms or
legs
2.67 Lack of appetite 2.64
7 I don’t look like
myself
2.67 Difficulty sleeping 2.63
8 Dry mouth 2.66 Pain 2.62
Table 8 Differences between younger (< 60, n = 263) and
older (≥ 60, n = 330) patients in rankings of symptoms
with the highest occurrence, severity, frequency, and
distress ratings (Continued)











1 Constipation 2.09 Problems with sexual
interest
2.03
2 Problems with sexual
interest
2.08 Constipation 1.80
3 Lack of energy 2.04 Problems with
urination
1.70
4 Pain 2.01 Pain 1.69
5 Difficulty sleeping 2.01 Difficulty sleeping 1.66
6 Worrying 1.93 Lack of energy 1.64
7 I don’t look like
myself
1.89 Difficulty swallowing 1.63
8 Feeling sad 1.87 Swelling of arms or
legs
1.58
9 Feeling bloated 1.85 Shortness of breath 1.47
10 Nausea 1.84 Worrying 1.46
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http://www.biomedcentral.com/1471-2407/13/6pituitary axis (HPA) that mediate the occurrence and se-
verity of the most common cancer-related symptoms
[44].
Another plausible hypothesis for the lower symptom
occurrence rates in older patients is that older persons
may experience a “response shift” in their perception
of symptoms. A “response shift” is defined as an age-
related psychological shift that represents a change in a
person’s internal framework for the assessment of experi-
ences [45]. This concept was first used in oncology to de-
scribe changes over time in QOL [46]. In the context of
older patients’ reports of symptoms, these individuals may
have experienced an internal reconceptualization of their
symptom experience based on their lifetime experience
with symptoms or their experience with symptoms from
other chronic medical conditions [45]. In addition, based
on studies of barriers to pain assessment and management
in older adults [47], older patients tend to under-report
pain because: they view it as a normal part of aging; they
are concerned that if they report pain it will distract their
clinician from treating their cancer; they are fearful about
additional diagnostic tests and their associated costs; or
they are worried about additional treatments (e.g., opioid
analgesics for pain) and associated adverse events
[11,48,49]. It is plausible that these same barriers contrib-
ute to under-reporting of other symptoms in older adults.
Cough and shortness of breath were among the top most
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group. In contrast, feeling sad and sweats were unique to
the younger age group. These differences in patterns of
occurrence warrant investigation in future studies.
For older and younger patients who reported a specific
symptom, severity ratings for the majority of the symp-
toms were mild to moderate. For all but six symptoms
(i.e., dry mouth, feeling drowsy, feeling sad, sweats,
worrying, I don’t look like myself ), no age-related differ-
ences in severity scores were reported (see Table 3). In
addition to the hypotheses stated above, several potential
explanations for the lack of differences in symptom se-
verity ratings warrant consideration. If younger patients
received higher doses of RT and/or CTX than older
patients, one would expect higher symptom severity
scores in the younger group. One potential explanation
for the equivalent symptom severity scores is that
younger patients received more aggressive symptom
management than older patients. This hypothesis is sup-
ported by studies that found that older patients receive
lower doses of opioid analgesics than younger patients
with comparable pain severity scores [50,51].
In terms of the occurrence rates for specific symptoms
(see Table 8), seven of the ten symptoms with the high-
est severity ratings were the same in both age groups
(i.e., problems with sexual interest, hair loss, constipa-
tion, difficulty sleeping, swelling of arms or legs, lack of
energy, pain). A similar pattern for the most severe symp-
toms across age groups suggests that these symptoms are
common across cancer treatments. The age differential in
terms of actual severity ratings may be related to dose
reductions in the elderly or due to other biological or
psychological mechanisms described above. Similar hy-
potheses could be proposed to explain the age-related
differences in the symptom frequency ratings.
While a “response shift” in older persons’ perceptions
of their symptoms is a plausible explanation for the
lower occurrence rates for over 50% of the MSAS symp-
toms, one might ask why this same hypothesis does not
seem to apply for the other dimensions of the symptom
experience. One reason that a “response shift” may not
be as evident in patients’ ratings of symptom severity,
frequency, and distress is that the age group compari-
sons for these three dimensions were done with only
patients who reported the symptom. To verify this hy-
pothesis, differences in symptom severity scores between
older and younger patients were re-analyzed with the
inclusion of patients who did not report each symptom
(i.e., symptom severity scores ranged from 0 to 4 instead
of from 1 to 4). In these analyses, compared to younger
patients, older patients reported significantly lower se-
verity scores for: difficulty concentrating, pain, lack of
energy, feeling nervous, nausea, feeling drowsy, difficulty
sleeping, feeling bloated, vomiting, feeling sad, problemswith sexual interest, feeling irritable, worrying, I don’t
look like myself, and changes in skin. This finding sug-
gests that in older patients who develop a symptom as a
result of their cancer or its treatment, they experience it
with a similar severity as younger patients. The reasons
why some older patients do and do not experience can-
cer symptoms warrants investigation in future studies.
Besides occurrence, the largest number of age-related
differences were found in the symptom distress ratings
(i.e., for 43.8% of the symptoms, older patients reported
significantly lower ratings). Symptom distress is defined
as the degree or amount of physical or mental upset, an-
guish, or suffering experienced from a specific symptom
[26,52]. In one review [39], out of 22 studies that
assessed multiple symptoms in cancer patients, only
seven (31.8%) assessed distress. Of those seven, three
used the MSAS [39]. While no studies were found that
evaluated for age differences in MSAS symptom distress
ratings, the symptoms with the highest distress ratings
in our study are comparable to those found in other
studies that used the MSAS [53-55].
As shown in Table 8, six of the ten most distressing
symptoms were the same in both age groups (i.e., consti-
pation, problems with sexual interest, lack of energy,
pain, difficulty sleeping, worrying). Problems with urin-
ation, difficulty swallowing, swelling of the arms or legs,
and shortness of breath were among the top most dis-
tressing symptoms in the older age group. In contrast,
I don’t look like myself, feeling sad, feeling bloated, and
nausea were unique to the younger age group. These dif-
ferences in distress patterns warrant additional research.
Of note, no age-related differences were found in
symptom distress ratings for constipation and problems
with sexual interest. These two symptoms which oc-
curred in approximately 30% of the patients in both age
groups warrant a careful assessment because when they
do occur, they are severe, occur frequently, and are
distressing not only to older patients, but to younger
patients as well.
A surprising finding in this study was that a signifi-
cantly higher percentage (26%) of older patients reported
being fully active compared to younger patients (15.8%).
While older individuals in the general population are
more likely to report poorer functional status than
younger individuals [56], the higher functional status in
the older patients in this study may be attributed to
lower recruitment rates among the oldest old. An alter-
native explanation is that younger patients received
higher doses of CTX or RT that had a negative impact
on their functional status.
Despite the limitations enumerated earlier in the dis-
cussion, findings from this study provide valuable infor-
mation to guide clinical practice and research. As shown
in Table 8, across all four symptom dimensions, the
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toms are similar for both age groups. What differs is the
magnitude estimation for each dimension, with older
persons reporting lower rates of occurrence, severity,
frequency, and distress for some symptoms. Because the
age-related differences in symptom severity, frequency,
and distress scores were small, additional research is
warranted within each age group to determine the im-
pact of each dimension of a symptom on younger and
older patients’ functional status and QOL.
The findings summarized in Table 8 provide new
information on symptoms with the highest occurrence,
severity, frequency and distress ratings in both age
groups. This information can be used by clinicians to
guide their multidimensional symptom assessments of
older oncology patients. Future research needs to focus
on a detailed evaluation of patient (i.e., phenotypic and
genotypic characteristics) and clinical characteristics that
explain the age differences in the various dimensions of
the symptom experience described in this study.
Conclusions
This study is the first to evaluate for differences in mul-
tiple dimensions of symptom experience in older oncol-
ogy patients. For almost 50% of the MSAS symptoms,
older patients reported significantly lower occurrence
rates. While fewer age-related differences were found in
ratings of symptom severity, frequency, and distress, a
similar pattern was found across all three dimensions.
Future research needs to focus on a detailed evaluation
of patient and clinical characteristics (i.e., type and dose
of treatment) that explain the differences in symptom
experience identified in this study.
Abbreviations
CTX: Chemotherapy; ECOG: Eastern Cooperative Oncology Group;
FPS: Fatigue, Pain, and Sleep; HPA: Hypothalamic-adrenal-pituitary axis;
MSAS: Memorial Symptom Assessment Scale; QOL: Quality of life;
RT: Radiation therapy; UCSF: University of California, San Francisco.
Competing interests
The authors declare that there are no competing interests.
Authors’ contributions
JC drafted the manuscript, and participated in the interpretation of the data.
SP combined the datasets, conducted data analyses, and contributed to the
interpretation of the data, and the critical revision of the manuscript. BC
conducted analyses and participated in the critical revision of the
manuscript. HS contributed to the analysis, the interpretation of the data,
and critical revision of the manuscript. KA, BA, VB, JM, and LD contributed to
the interpretation of the data, and the critical revision of the manuscript, and
CR participated in the critical revision of the manuscript. PY and CM
conceived the concept and study design, coordinated the study, and
contributed to the interpretation, drafting, and critical revision of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This collaborative project was funded by Atlantic Philanthropies, and a
Queensland University of Technology Institute of Health and Biomedical
Innovation Human Health and Wellbeing Collaborative Grant Scheme 2010.
The Australian study was funded under a Palliative Care National Health andMedical Research Council grant. The FPS study was funded by the National
Institute of Nursing Research (NR04835).
Author details
1School of Nursing, University of California, 2 Koret Way – N631Y, San
Francisco, CA 94143-0610, USA. 2Schools of Nursing Medicine, University of
California, 2 Koret Way – N631Y, San Francisco, CA 94143-0610, USA. 3School
of Nursing, Queensland University of Technology, Victoria Park Road, Kelvin
Grove 4059Queensland, Australia. 4Institute for Human Genetics, University of
California, 2 Koret Way – N631Y, San Francisco, CA 94143-0610, USA.
5Department of Physiological Nursing, University of California, 2 Koret
Way – N631Y, San Francisco, CA 94143-0610, USA.
Received: 20 December 2012 Accepted: 20 December 2012
Published: 3 January 2013
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
2. Balducci L: Supportive care in elderly cancer patients. Curr Opin Oncol
2009, 21:310–317.
3. Townsley C, Pond G, Peloza B, Kok J, Naidoo K, Dale D, Herbert C, Holowaty
E, Straus S, Siu L: Analysis of treatment practices for elderly cancer
patients in Ontario, Canada. J Clin Oncol 2005, 23:3802–3810.
4. Townsley G, Beck S, Watkins J: “Learning to live with it”: coping with the
transition to cancer survivorship in older adults. J Aging Stud 2007,
21:93–106.
5. Langer CJ: Clinical evidence on the undertreatment of older and poor
performance patients who have advanced non-small-cell lung cancer: Is
there a role for targeted therapy in these cohorts? Clin Lung Cancer 2011,
12:272–279.
6. Dale DC: Poor prognosis in elderly patients with cancer: the role of bias
and undertreatment. J Support Oncol 2003, 1(suppl 2):11–17.
7. Bastiaannet E, Portielje JEA, van de Velde CJH, de Craen AJM, van der Velde
S, Kuppen PJK, van der Geest LGM, Janssen-Heijnen MLG, Dekkers OM,
Westendorp RGJ: Lack of survival gain for elderly women with breast
cancer. Oncologist 2011, 16:415–423.
8. Kagan SH: Ageism in cancer care. Sem Oncol Nurs 2008, 24:246–253.
9. Kroenke CH, Rosner B, Chen WY, Kawachi I, Colditz GA, Holmes MD:
Functional impact of breast cancer by age at diagnosis. J Clin Oncol 2004,
22:1849–1856.
10. Cheung WY, Le LW, Gagliese L, Zimmermann C: Age and gender
differences in symptom intensity and symptom clusters among patients
with metastatic cancer. Support Care Cancer 2011, 19:417–423.
11. Carreca I, Balducci L: Cancer chemotherapy in the older cancer patient.
Urol Oncol 2009, 27:633–642.
12. Brunello A, Loaldi E, Balducci L: Dose adjustment and supportive care
before and during treatment. Cancer Treat Rev 2009, 35:493–498.
13. Kumar A, Soares H, Balducci L, Djulbegovic B: Treatment tolerance and
efficacy in geriatric oncology: a systematic review of phase III
randomized trials conducted by five National Cancer Institute-sponsored
cooperative groups. J Clin Oncol 2007, 25:1272–1276.
14. Rose J, O'Toole E, Dawson N, Thomas C, Connors A Jr, Wenger N, Phillips R,
Hamel M, Cohen H, Lynn J: Age differences in care practices and
outcomes for hospitalized patients with cancer. J Am Geriatr Soc 2000,
48:S25–S32.
15. Mohile SG, Heckler C, Fan L, Mustian K, Jean-Pierre P, Usuki K, Sprod L,
Janelsins M, Purnell J, Peppone L, et al: Age-related differences in
symptoms and their interference with quality of life in 903 cancer
patients undergoing radiation therapy. J Geriatr Oncol 2011, 2:225–232.
16. Degner L, Sloan J: Symptom distress in newly diagnosed ambulatory
cancer patients and as a predictor of survival in lung cancer. J Pain
Symptom Manage 1995, 10:423–431.
17. Yan H, Sellick K: Symptoms, psychological distress, social support, and
quality of life of Chinese patients newly diagnosed with gastrointestinal
cancer. Cancer Nurs 2004, 27:389–399.
18. Avis NE, Crawford S, Manuel J: Quality of life among younger women with
breast cancer. J Clin Oncol 2005, 23:3322–3330.
19. Ellis J, Lin J, Walsh A, Lo C, Shepherd FA, Moore M, Li M, Gagliese L,
Zimmermann C, Rodin G: Predictors of referral for specialized
psychosocial oncology care in patients with metastatic cancer: the
Cataldo et al. BMC Cancer 2013, 13:6 Page 16 of 16
http://www.biomedcentral.com/1471-2407/13/6contributions of age, distress, and marital status. J Clin Oncol 2009,
27:699–705.
20. Graves KD, Arnold SM, Love CL, Kirsh KL, Moore PG, Passik SD: Distress
screening in a multidisciplinary lung cancer clinic: prevalence and
predictors of clinically significant distress. Lung Cancer 2007,
55:215–224.
21. Politi MC, Enright TM, Weihs KL: The effects of age and emotional
acceptance on distress among breast cancer patients. Support Care
Cancer 2007, 15:73–79.
22. Goldzweig G, Hubert A, Walach N, Brenner B, Perry S, Andritsch E, Baider L:
Gender and psychological distress among middle-and older-aged
colorectal cancer patients and their spouses: an unexpected outcome.
Crit Rev Oncol Hematol 2009, 70:71–82.
23. Weiss T, Weinberger MI, Holland J, Nelson C, Moadel A: Falling through the
cracks: a review of psychological distress and psychosocial service needs
in older Black and Hispanic patients with cancer. J Geriatr Oncol 2012,
3(2):163–173.
24. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown
ML: Cost of care for elderly cancer patients in the United States.
J Nat Cancer Inst 2008, 100:630–641.
25. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA: Future of
cancer incidence in the United States: burdens upon an aging, changing
nation. J Clin Oncol 2009, 27:2758–2765.
26. Portenoy RK, Thaler HT, Kornblith AB, McCarthy Lepore J, Friedlander-Klar H,
Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L: The memorial symptom
assessment scale: an instrument for the evaluation of symptom
prevalence, characteristics and distress. Eur J Cancer 1994, 30:1326–1336.
27. Kim H, Barsevick A, Tulman L: Predictors of the intensity of symptoms in a
cluster in patients with breast cancer. J Nurs Scholar 2009, 41:158–165.
28. Brant J, Beck S, Dudley W, Cobb P, Pepper G, Miaskowski C: Symptom
trajectories in posttreatment cancer survivors. Cancer Nurs 2010, 34:67–77.
29. Hopwood P, Haviland J, Mills J, Sumo G: The impact of age and clinical
factors on quality of life in early breast cancer: an analysis of 2208
women recruited to the UK START Trial (Standardisation of Breast
Radiotherapy Trial). Breast 2007, 16:241–251.
30. Gagliese L, Jovellanos M, Zimmermann C, Shobbrook C, Warr D, Rodin G:
Age-related patterns in adaptation to cancer pain: a mixed method
study. Pain Med 2009, 10:1050–1061.
31. Gagliese L, Melzack R: Age-related differences in the qualities but not the
intensity of chronic pain. Pain 2003, 104:597–608.
32. Zubrod CG, Schneiderman M, Frei E, Brindley C, Gold GL, Shnider B:
Appraisal of methods for the study of chemotherapy of cancer in man:
comparative therapeutic trial of nitrogen mustard and triethylene
thiophosphoramide. J Chron Dis 1960, 11:7–33.
33. Verger E, Salamero M, Conill C: Can Karnofsky performance status be
transformed to the Eastern Cooperative Oncology Group scoring scale
and vice versa? Eur J Cancer 1992, 28:1328–1330.
34. Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng K, Marshall T: The risk
of colorectal cancer with symptoms at different ages and between the
sexes: a case–control study. BMC Med 2009, 7(1):17.
35. Stark LL, Tofthagen C, Visovsky C, McMillan SC: The symptom experience
of patients with cancer. J Hosp Palliat Nurs 2012, 14:61–70.
36. Dodd MJ, Miaskowski C, Paul SM: Symptom clusters and their effect on
the functional status of patients with cancer. Oncol Nurs Forum 2001,
28:465–470.
37. Dodd MJ, Miaskowski C, Lee KA: Occurrence of symptom clusters.
JNCI Monographs 2004, 32:76–78.
38. Kim EJ, Dodd M, Aouizerat B, Jahan T, Miaskowski C: A review of the
prevalence and impact of multiple symptoms in oncology patients.
J Pain Symptom Manage 2009, 37:715–736.
39. Gilbertson-White S, Aouizerat BE, Jahan T, Miaskowski C: A review of the
literature on multiple symptoms, their predictors, and associated
outcomes in patients with advanced cancer. Palliat Support Care 2011,
9:81–102.
40. Hamaker M, Schreurs W, van Slooten H, Uppelschoten J, Smorenburg C:
Trends in breast cancer treatment in the elderly at a breast cancer
outpatient clinic: guidelines followed better. Ned Tijdsch Geneeskd 2009,
153:A562.
41. McLachlan AJ, Pont LG: Drug metabolism in older people—a key
consideration in achieving optimal outcomes with medicines. J Gerontol
A Biol Sci Med Sci 2012, 67:175–180.42. Kahana E, Kahana B, Kelley-Moore J, Adams SA, Hammel R, Kulle D, Brown
JA, King C: Toward advocacy in cancer care for older adults: survivors
have cautious personal actions but bold advice for others. J Am Geriatr
Soc 2009, 57:S269–S271.
43. Lenze EJ, Wetherell JL: A lifespan view of anxiety disorders. Dialogues Clin
Neurosci 2011, 13:381–399.
44. Bower JE, Low CA, Moskowitz JT, Sepah S, Epel E: Benefit finding and
physical health: positive psychological changes and enhanced allostasis.
Soc Personal Psychol Compass 2008, 2:223–244.
45. Costanzo ES, Ryff CD, Singer BH: Psychosocial adjustment among cancer
survivors: findings from a national survey of health and well-being.
Health Psycho 2009, 28:147–156.
46. Schwartz CE, Sprangers MAG: Methodological approaches for assessing
response shift in longitudinal health-related quality-of-life research.
Soc Sci Med 1999, 48:1531–1548.
47. Herr K, Titler MG, Schilling ML, Marsh JL, Xie X, Ardery G, Clarke WR, Everett
LQ: Evidence-based assessment of acute pain in older adults: current
nursing practices and perceived barriers. Clin J Pain 2004, 20:331–340.
48. Pain(PDQ). http://www.cancer.gov/cancertopics/pdq/supportivecare/pain/
HealthProfessional/page1.
49. Ferrell BA: Pain management in elderly people. J Am Geriatr Soc 1991,
39:64–73.
50. Urban D, Cherny N, Catane R: The management of cancer pain in the
elderly. Crit Rev Oncol Hematol 2010, 73:176–183.
51. Delgado-Guay MO, Bruera E: Management of pain in the older person
with cancer. Part 1. Oncology 2008, 22:148–152.
52. Rhodes VA, Watson PM: Symptom distress–the concept: past and present.
Sem Oncol Nurs 1987, 3:242–247.
53. McMillan SC, Small BJ: Symptom distress and quality of life in patients
with cancer newly admitted to hospice home care. Oncol Nurs Forum
2002, 29:1421–1428.
54. Peters L, Sellick K: Quality of life of cancer patients receiving inpatient
and home-based palliative care. J Adv Nurs 2006, 53:524–533.
55. Rodin G, Zimmermann C, Rydall A, Jones J, Shepherd FA, Moore M, Fruh M,
Donner A, Gagliese L: The desire for hastened death in patients with
metastatic cancer. J Pain Symptom Manage 2007, 33:661–675.
56. Sergi G, Sarti S, Mosele M, Ruggiero E, Imoscopi A, Miotto F, Bolzetta F,
Inelmen EM, Manzato E, Coin A: Changes in healthy elderly women's
physical performance: a 3-year follow-up. Exp Gerontol 2011, 46:929–933.
doi:10.1186/1471-2407-13-6
Cite this article as: Cataldo et al.: Differences in the symptom
experience of older versus younger oncology outpatients: a cross-
sectional study. BMC Cancer 2013 13:6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
